VivoSeq
Immunology

Systemic Lupus Erythematosus (SLE)

4

Pipeline Programs↗

7

Active Trials↗

7

Companies Involved↗

Systemic Lupus Erythematosus (SLE) is an early-stage landscape with 4 programs across 7 companies. The most active players are Biogen, Pfizer, Merck & Co.. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Biogen logo

Biogen

2 programs

Phase 3Pfizer logo

Pfizer

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Novartis logo

Novartis

1 program

Phase 3EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

3programs
Small molecule133%
Monoclonal antibody133%
Cell therapy133%

Modality classified for 70% of 10 pipeline programs.

Analysis

Trial Status

8

clinical trials

Recruiting4 · 50%
Enrolling by invitation2 · 25%
Active, not recruiting1 · 13%
Completed1 · 13%

Clinical Trials

Trial Activity

8 trials

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·Preclinical·NCT06032923·78 enrolled
A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-1)
Recruiting·EMD Serono Research & Development Institute, Inc. logoEMD Serono Research & Development Institute, Inc.·Phase 3·NCT07332481·202 enrolled
INTERSTELLAR - Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT06314282·200 enrolled
A Clinical Study of the Safety and Efficacy of Universal Anti-CD70 CAR-T (CHT101) for the Treatment of Relapsed and Refractory Systemic Lupus Erythematosus
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1·NCT06946485·15 enrolled
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol
Active, not recruiting·UUniversity Hospital, Brest·Phase 3·NCT05458622·25 enrolled
A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus
Enrolling by invitation·Biogen logoBiogen·Phase 3·NCT05352919·864 enrolled
Study on Early Visual Dysfunction in Patients With Systemic Lupus Erythematosus
Enrolling by invitation·TThe First Affiliated Hospital of Anhui Medical University·N/A·NCT07679776·100 enrolled
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2
Completed·UUniversity Hospital, Brest·N/A·NCT05747651·6 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)